Sensei Biotherapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Faeth Therapeutics,

05/05/2025 13:49

Sensei Biotherapeutics Inc SNSE.OQ SNSE.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Sensei Biotherapeutics Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 2.1% in the last three months. ​

Wall Street's median 12-month price target for Sensei Biotherapeutics Inc is $4.00​, above​ its last closing price of $0.42. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.29
-0.28
-0.31
Missed
-12
Sep. 30 2024
-0.31
-0.31
-0.29
Beat
7.2
Jun. 30 2024
-0.30
-0.29
-0.28
Beat
2.9​
Mar. 31 2024
-0.27
-0.27
-0.32
Missed
-16.4
​​Dec. 31 2023
-0.31
-0.31
-0.30
Beat
2.5
Sep. 30 2023
-0.34
-0.34
-0.28
Beat
17.4​
Jun. 30 2023
-0.33
-0.33
-0.31
Beat
6.2
Mar. 31 2023
-0.36
-0.36
-0.33
Beat
7.3

This summary was machine generated May 5 at 12:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)